Trial Watch: Toll-like receptor agonists in cancer immunotherapy

Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncoimmunology
Autori principali: Smith, Melody, García-Martínez, Elena, Pitter, Michael R., Fucikova, Jitka, Spisek, Radek, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2018
Soggetti:
Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6279325/
https://ncbi.nlm.nih.gov/pubmed/30524908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1526250
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi